Mivazerol 是一种选择性 α2-肾上腺素受体 (α2-adrenoceptor) 激动剂,可降低血清素 (5-HT) 的自发性释放,显著抑制束缚应激诱导的去甲肾上腺素 (NE)、多巴胺 (DA) 和二羟苯乙酸 (DOPAC) 水平升高,抑制大鼠氟烷戒断诱发的鞘内谷氨酸释放,对前脑缺血大鼠发挥神经保护作用,并可用于心肌缺血相关研究。
产品编号: MS-G44814 CAS No.: 125472-02-8 分子式: C11H11N3O2 分子量: 217.22
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Mivazerol 是一种选择性 α2-肾上腺素受体 (α2-adrenoceptor) 激动剂,可降低血清素 (5-HT) 的自发性释放,显著抑制束缚应激诱导的去甲肾上腺素 (NE)、多巴胺 (DA) 和二羟苯乙酸 (DOPAC) 水平升高,抑制大鼠氟烷戒断诱发的鞘内谷氨酸释放,对前脑缺血大鼠发挥神经保护作用,并可用于心肌缺血相关研究。

生物实验数据

生物活性 Mivazerol is a selective α2-adrenoceptor agonist that reduces the spontaneous release of serotonin (5-HT), significantly inhibits restraint stress-induced elevations in norepinephrine (NE), dopamine (DA), and 3,4-dihydroxyphenylacetic acid (DOPAC) levels, suppresses halothane withdrawal-induced intrathecal glutamate release in rats, exerts neuroprotective effects in rats with forebrain ischemia, and can be used in studies related to myocardial ischemia.
IC50 & Target

α2-adrenergic receptor

 

体外研究
(In Vitro)

Mivazerol 对 α2a-α1 的选择性比率为 119,其特异性介于 Clonidine (MS-P68934) 与 dexmedetomidine (MS-T95309) 之间。

体内研究
(In Vivo)

Mivazerol (15 μg/kg/h;静脉注射;持续输注;氟烷停用前 30 分钟开始) 可抑制大鼠因氟烷停用诱发的谷氨酸鞘内释放。
Mivazerol (2.5 μg/kg;鞘内注射;1 分钟内微量注射;氟烷停用前 2 分钟) 可抑制大鼠中由氟烷停用诱发的谷氨酸鞘内释放。
Mivazerol (10-40 μg/kg;皮下注射;单次给药;缺血前 30 分钟) 在大鼠前脑缺血模型中发挥神经保护作用。

Animal Model: Male Sprague-Dawley rats (250-400 g) anesthetized with 1.1% halothane then subjected to halothane withdrawal
Dosage: 15 μg/kg/h
Administration: continuous infusion; starting 30 minutes prior to halothane withdrawal
Result: Reduced the maximal halothane withdrawal-induced HR increase and reduced the maximal intrathecal glutamate release.
Attenuated the aspartate response but had no significant effect on BP response.
Animal Model: Male Sprague-Dawley rats (250-400 g) anesthetized with 1.1% halothane then subjected to halothane withdrawal
Dosage: 2.5 μg/kg
Administration: i.t.; microinjection over 1 minute; 2 minutes prior to halothane withdrawal
Result: Reduced the maximal halothane withdrawal-induced HR increase and reduced the maximal intrathecal glutamate release, with inhibition lasting at least 60 minutes post-withdrawal.
Had no significant effect on BP or aspartate responses with intrathecal administration.
Animal Model: Male Sprague-Dawley rats (300-400 g) with forebrain ischemia
Dosage: 10; 20; 40 μg/kg
Administration: s.c.; single dose; 30 min pre-ischemia
Result: Reduced 7-day survival rate to 40% in the 40 μg/kg group, compared to 90% in the 10 μg/kg and 20 μg/kg groups.
Recorded median neurologic deficit scores (NDS) of 10.0 at 24 h, 27.5 at 48 h, and ~5 at 7 days for the 10 μg/kg group; 30.0 at 24 h, 27.5 at 48 h, and ~5 at 7 days for the 20 μg/kg group; 43.0 at 24 h, 100.0 at 48 h, and 100 at 7 days for the 40 μg/kg group.
Observed significantly greater number of intact neurons in the hippocampal CA1 subfield in the 20 μg/kg group than in all other groups.
Lowered neocortex damage scores significantly in the 20 μg/kg group compared to the control and 40 μg/kg groups.

化学信息

分子量 217.22
分子式 C11H11N3O2
CAS No. 125472-02-8

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础